ANDA 40163, held by Specgx LLC. Meperidine Hydrochloride.
As of Nov 16, 2026, ANDA 40163 (Meperidine Hydrochloride Preservative Free), held by Specgx LLC, was first approved by FDA on May 12, 1997, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 12, 1997 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Meperidine Hydrochloride Preservative Free10MG/ML · injectable;injection | Meperidine Hydrochloride | Discontinued |
| Dec 15, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 11, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 23, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 16, 2016 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 16, 2016 | Supplement 2Labeling · Standard review | Approved | None posted |
| May 12, 1997 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters